These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 31115638)

  • 21. 225Ac-PSMA-617 Radioligand Posttherapy Imaging in Metastatic Castrate-Resistant Prostate Cancer Patient Using 3 Photopeaks.
    Vatsa R; Sood A; Vadi SK; Das CK; Kaur K; Parmar M; Mittal BR
    Clin Nucl Med; 2020 Jun; 45(6):437-438. PubMed ID: 32366786
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer].
    Fendler WP; Kratochwil C; Ahmadzadehfar H; Rahbar K; Baum RP; Schmidt M; Pfestroff A; Lützen U; Prasad V; Heinzel A; Heuschkel M; Ruf J; Bartenstein P; Krause BJ
    Nuklearmedizin; 2016 Jun; 55(3):123-8. PubMed ID: 27350005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.
    Kabasakal L; AbuQbeitah M; Aygün A; Yeyin N; Ocak M; Demirci E; Toklu T
    Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1976-83. PubMed ID: 26227531
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [PSMA radioligand therapy in patients with advanced prostate cancer].
    Bögemann M; Herrmann K; Radtke JP; Rahbar K
    Urologe A; 2020 Jun; 59(6):680-686. PubMed ID: 32333064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metastatic Prostate Cancer With Restored Hormone-Response After Radioligand Therapy With 177Lu-PSMA-617.
    Schlenkhoff CD; Knüpfer E; Essler M; Ahmadzadehfar H
    Clin Nucl Med; 2016 Jul; 41(7):572-3. PubMed ID: 26909718
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resistant Prostate Carcinoma.
    Khawar A; Eppard E; Sinnes JP; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA
    Clin Nucl Med; 2018 Jul; 43(7):486-491. PubMed ID: 29688951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TheraP: a randomized phase 2 trial of
    Hofman MS; Emmett L; Violet J; Y Zhang A; Lawrence NJ; Stockler M; Francis RJ; Iravani A; Williams S; Azad A; Martin A; McJannett M; ; Davis ID
    BJU Int; 2019 Nov; 124 Suppl 1():5-13. PubMed ID: 31638341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Posttherapeutic Critical Organ Dosimetry of Extensive 177Lu-PSMA Inhibitor Therapy With Metastatic Castration-Resistant Prostate Cancer: One Center Results.
    Özkan A; Uçar B; Seymen H; Yildiz Yarar Y; Falay FO; Demirkol MO
    Clin Nucl Med; 2020 Apr; 45(4):288-291. PubMed ID: 32049721
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radiation Dosimetry for
    Okamoto S; Thieme A; Allmann J; D'Alessandria C; Maurer T; Retz M; Tauber R; Heck MM; Wester HJ; Tamaki N; Fendler WP; Herrmann K; Pfob CH; Scheidhauer K; Schwaiger M; Ziegler S; Eiber M
    J Nucl Med; 2017 Mar; 58(3):445-450. PubMed ID: 27660138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer.
    Kratochwil C; Bruchertseifer F; Giesel FL; Weis M; Verburg FA; Mottaghy F; Kopka K; Apostolidis C; Haberkorn U; Morgenstern A
    J Nucl Med; 2016 Dec; 57(12):1941-1944. PubMed ID: 27390158
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BRCA2 Mutation as a Possible Cause of Poor Response to 177Lu-PSMA Therapy.
    Ahmadzadehfar H; Gaertner F; Lossin PS; Schwarz B; Essler M
    Clin Nucl Med; 2018 Aug; 43(8):609-610. PubMed ID: 29762244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617.
    Ferdinandus J; Eppard E; Gaertner FC; Kürpig S; Fimmers R; Yordanova A; Hauser S; Feldmann G; Essler M; Ahmadzadehfar H
    J Nucl Med; 2017 Feb; 58(2):312-319. PubMed ID: 27587707
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cocktail Therapy of 177Lu-PSMA-617 and 177Lu-EDTMP in Patients With mCRPC: A Proof-of-Principle Application.
    Bal C; Yadav MP; Ballal S
    Clin Nucl Med; 2016 Aug; 41(8):e386-7. PubMed ID: 27187728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Additional Local Therapy for Liver Metastases in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Systemic PSMA-Targeted Therapy.
    Seifert R; Kessel K; Boegemann M; Köhler M; Roll W; Stegger L; Weckesser M; Rahbar K
    J Nucl Med; 2020 May; 61(5):723-728. PubMed ID: 31601703
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Yadav MP; Ballal S; Tripathi M; Damle NA; Sahoo RK; Seth A; Bal C
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):81-91. PubMed ID: 27506431
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted alpha therapy in a systemic mouse model of prostate cancer - a feasibility study.
    Stuparu AD; Meyer CAL; Evans-Axelsson SL; Lückerath K; Wei LH; Kim W; Poddar S; Mona CE; Dahlbom M; Girgis MD; Radu CG; Czernin J; Slavik R
    Theranostics; 2020; 10(6):2612-2620. PubMed ID: 32194823
    [No Abstract]   [Full Text] [Related]  

  • 37. Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer.
    Yadav MP; Ballal S; Tripathi M; Damle NA; Sahoo RK; Seth A; Bal C
    Nucl Med Commun; 2017 Jan; 38(1):91-98. PubMed ID: 27782913
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complete Regression of Lung Metastases in a Patient With Metastatic Castration-Resistant Prostate Cancer Using 177Lu-PSMA Radioligand Therapy.
    Zhang J; Kulkarni HR; Singh A; Baum RP
    Clin Nucl Med; 2020 Jan; 45(1):e48-e50. PubMed ID: 31162261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PSMA PET applications in the prostate cancer journey: from diagnosis to theranostics.
    Eapen RS; Nzenza TC; Murphy DG; Hofman MS; Cooperberg M; Lawrentschuk N
    World J Urol; 2019 Jul; 37(7):1255-1261. PubMed ID: 30374609
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing
    Rathke H; Kratochwil C; Hohenberger R; Giesel FL; Bruchertseifer F; Flechsig P; Morgenstern A; Hein M; Plinkert P; Haberkorn U; Bulut OC
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):139-147. PubMed ID: 30151743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.